Fibrolamellar carcinomas are positive for CD68

Modern Pathology

Volumn 24, Issue 3, 2011, Pages 390-395

  Ross, Hillary M ^a   Daniel, Hubert D J ^a   Vivekanandan, Perumal ^a   Kannangai, Rajesh ^a   Yeh, Matthew M ^b   Wu, Tsung Teh ^c   Makhlouf, Hala R ^d   Torbenson, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

CD68; cholangiocarcinoma; fibrolamellar carcinoma; hepatocellular carcinoma

Indexed keywords

CD68 ANTIGEN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIBROLAMELLAR CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952195361     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.207     Document Type: Article

References (10)

1. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14: 217-223. (Pubitemid 46659192)
2. Malouf G, Falissard B, Azoulay D, et al. Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 2009;62:519-524.
3. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803. (Pubitemid 38337660)
4. Vivekanandan P, Micchelli ST, Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol 2009;40:293-299.
5. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol 2005;124:512-518. (Pubitemid 41395631)
6. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007;38:639-644. (Pubitemid 46399897)
7. Biosystems A. Guide to performing relative quantita-tion of gene expression using real-time quantitative PCR. http://www3.appliedbiosystems.com/ cms/ groups/mcb-support/documents/generaldocuments/ cms-042380.pdf, 2010.
8. Abdul-Al HM, Wang G, Makhlouf HR, et al. Fibrolamel-lar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. Int J Surg Pathol 2010;18:313-318.
9. Ward SC, Huang J, Tickoo SK, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-1190.
10. Kaiserling E, Ruck P, Xiao JC. Immunoreactivity of neoplastic and non-neoplastic hepatocytes for CD68 and with 3A5, Ki-M1P, and MAC387 light and electron microscopic findings. Int Hepatol Commun 1995;3: 322-329.